Trazimera®
ACTIVE PRINCIPLE:
Trastuzumab
INDICATION:
breast and stomach cancer
DATE:
30/11/2018
STATUS:
Authorized
Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE:
Trastuzumab
INDICATION:
breast and stomach cancer
DATE:
30/11/2018
STATUS:
Authorized
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.